The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

Between 2020 and 2024, 53 combination therapies applied for expanded reimbursement, but only one cross-company case (Braftovi and Erbitux for colorectal cancer) was approved, according to data ...

Held at the SM Mall of Asia Arena, the Autism Society Philippines’ Angels Walk 2025 brought together over 40,000 advocates in a nationwide movement for autism appreciation, accommodation, and ...

Two-drug therapy with Braftovi and Erbitux also performed well, with an OS of 8.4 months. Kopetz tweeted that the response rates in second-line patients was 34% for the triplet, 22% for the ...

MoA Core Bond Fund earns an Above Average Process Pillar rating. The most important driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's ...

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential. Total return includes interest, capital ...

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers. The Oncodetect test detects molecular residual ...

NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...